Enaminones and norepinephrine employ convergent mechanisms to depress excitatory synaptic transmission in the rat nucleus accumbens in vitro

Eur J Neurosci. 2006 Nov;24(10):2781-8. doi: 10.1111/j.1460-9568.2006.05152.x.

Abstract

We recently reported that anticonvulsant anilino enaminones depress excitatory postsynaptic currents (EPSCs) in the nucleus accumbens (NAc) indirectly via gamma-aminobutyric acid (GABA) acting on GABA(B) receptors [S.B. Kombian et al. (2005)Br. J. Pharmacol., 145, 945-953]. Norepinephrine (NE) and dopamine (DA), both known to be involved in seizure disorders, also depress EPSCs in this nucleus. The current study explored a possible interaction between enaminones and adrenergic and/or dopaminergic mechanisms that may contribute to their synaptic depression and anticonvulsant effect. Using whole-cell recording in rat forebrain slices containing the NAc, we show that NE-induced, but not DA-induced, EPSC depression occludes E139-induced EPSC depressant effect. UK14,304, a selective alpha(2) receptor agonist, mimicked the synaptic effect of NE and also occluded E139 effects. Phentolamine, a non-selective alpha-adrenergic antagonist that blocked NE-induced EPSC depression, also blocked the E139-induced EPSC depression. Furthermore, yohimbine, an alpha(2)-adrenoceptor antagonist, also blocked the E139-induced EPSC depression, while prazosin, a selective alpha(1)-adrenergic antagonist, and propranolol, a non-selective beta-adrenoceptor antagonist, did not block the E139 effect. Similar to the E139-induced EPSC depression, the NE-induced EPSC depression was also blocked by the GABA(B) receptor antagonist, CGP55845. By contrast, however, neither SCH23390 nor sulpiride, D1-like and D2-like DA receptor antagonists, respectively, blocked the E139-induced synaptic depression. These results suggest that NE and E139, but not DA, employ a similar mechanism to depress EPSCs in the NAc, and support the hypothesis that E139, like NE, may act on alpha(2)-adrenoceptors to cause the release of GABA, which then mediates synaptic depression via GABA(B) receptors.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic alpha-Agonists / pharmacology
  • Adrenergic alpha-Antagonists / pharmacology
  • Animals
  • Brimonidine Tartrate
  • Cyclohexanes / pharmacology
  • Dopamine / pharmacology
  • Drug Interactions
  • Electric Stimulation / methods
  • Excitatory Postsynaptic Potentials / drug effects*
  • Excitatory Postsynaptic Potentials / physiology
  • Excitatory Postsynaptic Potentials / radiation effects
  • GABA Antagonists / pharmacology
  • In Vitro Techniques
  • Male
  • Neural Inhibition / drug effects*
  • Neural Inhibition / physiology
  • Neural Inhibition / radiation effects
  • Norepinephrine / pharmacology*
  • Nucleus Accumbens / cytology*
  • Nucleus Accumbens / drug effects
  • Nucleus Accumbens / radiation effects
  • Phosphinic Acids / pharmacology
  • Prazosin / pharmacology
  • Propanolamines / pharmacology
  • Quinoxalines / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Synaptic Transmission / drug effects*
  • Synaptic Transmission / radiation effects

Substances

  • Adrenergic alpha-Agonists
  • Adrenergic alpha-Antagonists
  • Cyclohexanes
  • E139 compound
  • GABA Antagonists
  • Phosphinic Acids
  • Propanolamines
  • Quinoxalines
  • CGP 55845A
  • Brimonidine Tartrate
  • Dopamine
  • Norepinephrine
  • Prazosin